Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema
Indian Journal of Ophthalmology · 2024
DOI: 10.4103/ijo.ijo_767_23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Ophthalmology, 2024. Verfasst von Santosh K Mahapatra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vitreo-retina Surgery, JPM Rotary Club of Cuttack Eye Hosiptal and Research Institute, Cuttack, Odisha, India. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Cataract, Diabetes Mellitus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
To compare the safety and efficacy parameters of intravitreal ranibizumab vs intravitreal dexamethasone (IVD) in the treatment of patients with naïve diabetic macular edema (DME) in terms of best-corrected visual acuity (BCVA), central macular thickness (CMT), and possible complications like intraocular pressure (IOP) rise and cataract progression.
Methods
A hospital-based prospective and comparative study of naïve DME patients was conducted between November 2020 and October 2021 with a minimum follow-up (F/U) period of 6 months. Thirty phakic patients received one dose of IVD implant (Group A) and the other 30 (Group B) received three consecutive monthly doses of ranibizumab. The main exclusion criteria were steroid responders and the presence of ocular inflammation.
Results
The mean pre-injection CMT in Group A was 405µ and reduced to 297.07µ at 3 months and 278.35µ at 6 months. Mean increase in logMAR BCVA was 0.55. The mean pre-injection IOP was 16.28 and 17.64 mm of Hg at 6 months. In Group B, the mean pre-injection CMT was 401.07µ and reduced to 276.1µ at 3 months and 292.9µ at 6 months. Mean BCVA increased to 0.37. The mean pre-injection IOP was 17.28 mm Hg and 16.42 mm Hg at 6 months. There was no significant progression of cataract in both groups.
Conclusion
The mean decrease in CMT was comparable in both the groups at 6 months F/U with an improvement of BCVA with no significant IOP fluctuation or cataract progression. Hence, IVD appears to be noninferior to ranibizumab in the treatment of naïve DME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Vitreo-retina Surgery, JPM Rotary Club of Cuttack Eye Hosiptal and Research Institute, Cuttack, Odisha, India.
- DNB Resident in Ophthalmology, JPM Rotary Club of Cuttack Eye Hosiptal and Research Institute, Cuttack, Odisha, India.
Zitieren
APA
Mahapatra, S. K., Parhi, A., Shree, P., & Mohanty, A. (2024). Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_767_23
Vancouver
Mahapatra SK, Parhi A, Shree P, Mohanty A. Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema. Indian Journal of Ophthalmology. 2024. doi:10.4103/ijo.ijo_767_23
BibTeX
@article{Mahapatra2024,
author = {Mahapatra, Santosh K and Parhi, Anjalika and Shree, Pallavi and Mohanty, Anuja},
title = {Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema},
journal = {Indian Journal of Ophthalmology},
year = {2024},
doi = {10.4103/ijo.ijo_767_23}
}
EUVIMED